

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:** Please amend the claims as follows:

**We claim:**

**Claims 1.-29. (Cancelled)**

**Claim 30. (Currently Amended)** A pharmaceutical composition comprising a first antibody molecule or a portion thereof and a second antibody molecule or a portion thereof, having the capability to bind to different epitopes located on an ErbB1 receptor molecule, wherein said first antibody molecule or a portion thereof comprises a binding site that bind to a first specific epitope on the ErbB1 receptor molecule, and said second antibody molecule comprises a binding site that binds to a second specific different epitope on said ErbB1 receptor molecule,

wherein said first and said second epitopes on the ErbB1 receptor molecule are located within the ErbB1 receptor ligand-binding domain, thereby increasing the amount of antibody bound per receptor and per cell by the same antibody dose and causing an enhanced ErbB1 blocking and/or inhibition and induction of down-regulation of ErbB1 receptor-specific pathway signaling as compared with a composition comprising said first or second antibody molecule only,

wherein said first antibody is ~~murine, chimeric, or humanized~~ MAb 425 (h425) ~~or~~ ~~murine, chimeric, or humanized~~ and said second antibody is chimeric MAb 225 (c225).

**Claim 31. (Cancelled)**

**Claim 32. (Cancelled)**

**Claim 33. (Previously Presented)** The pharmaceutical composition according to claim 30, wherein said receptor ligand-binding domain is the binding domain of the natural ligand of said ErbB1 receptor.

**Claim 34. (Previously Presented)** The pharmaceutical composition according to claim 30, wherein said composition exhibits enhanced induction of cross-linking and/or dimerization

of ErbB1 receptor molecule compared to a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule.

**Claim 35. (Previously Presented)** The pharmaceutical composition according to claim 30, further comprising a cytotoxic agent.

**Claim 36. (Previously Presented)** The pharmaceutical composition according to claim 35, wherein said cytotoxic agent is a chemotherapeutic agent.

**Claim 37. (Previously Presented)** The pharmaceutical composition according of claim 36, wherein said chemotherapeutic agent is cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, or bleomycin.

**Claim 38. (Previously Presented)** The pharmaceutical composition according of claim 35, wherein said cytotoxic agent is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.

**Claim 39. (Previously Presented)** A kit comprising the pharmaceutical composition of claim 30 in one package and a carrier in a second package.

**Claim 40. (Previously Presented)** A method of inhibiting tumor growth and/or metastasis comprising contacting said tumor with the pharmaceutical composition according of claim 30.